Skip to Main Content
Mental Health & Behavioral Research, Phase II

Ketamine for Adolescent Suicidality

What is the purpose of this trial?

The purpose of this study is to determine if intravenous ketamine reduces suicidal thinking compared to an active placebo (midazolam) in adolescents who have treatment resistant depression and a recent history of a suicide event (defined as a suicide attempt, emergency room evaluation for suicidal thinking, or a transition to inpatient care for suicidality in the past 120 days).

The primary objective of this study is to determine whether ketamine reduces suicidal ideation (as measured via the C-SSRS, recent ideation scale) relative to an active control, midazolam, 48-hours after first administration in adolescents with TRD at high suicide risk.

  • Trial with
    National Institutes of Health (NIH)
  • Ages
    13 years - 17 years
  • Gender
    Both

Contact Information

For more information about this study, including how to volunteer, contact Brooke Rivera

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    07/28/2024
  • Study HIC
    #2000029003